Carbonbiosciences is a biotechnology research company based in Boston, MA, focused on developing novel parvovirus gene therapy platforms for treating genetic diseases. Founded in 2021, the firm has raised series A funding and employs a team of scientists and engineers advancing therapeutic pipelines. The company aims to create scalable gene therapy solutions leveraging proprietary parvovirus vectors, with a pipeline that includes preclinical programs and collaborations with academic institutions to accelerate therapeutic development for rare genetic disorders.
Carbonbiosciences is profiled on the APIs.io network. Tagged areas include Biotechnology, GeneTherapy, Boston, Biotech, and Healthcare.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: carbonbiosciences
name: Carbonbiosciences
description: Carbonbiosciences is a biotechnology research company based in Boston, MA, focused on developing novel parvovirus
gene therapy platforms for treating genetic diseases. Founded in 2021, the firm has raised series A funding and employs
a team of scientists and engineers advancing therapeutic pipelines. The company aims to create scalable gene therapy solutions
leveraging proprietary parvovirus vectors, with a pipeline that includes preclinical programs and collaborations with academic
institutions to accelerate therapeutic development for rare genetic disorders.
url: https://raw.githubusercontent.com/api-evangelist/carbonbiosciences/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment pass 2026-10-09 (modular-v1; was harvest)
specificationVersion: '0.20'
created: '2026-10-07'
modified: '2026-10-07'
tags:
- Biotechnology
- GeneTherapy
- Boston
- Biotech
- Healthcare
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Hosts
url: hosts/carbonbiosciences-hosts.yml
- type: Vendors
url: vendors/carbonbiosciences-vendors.yml
- type: DomainSecurity
url: security/carbonbiosciences-domain-security.yml
- type: Website
url: https://equityzen.com/company/carbonbiosciences
apis: []
x-coverage:
state: blocked
reason: bot-challenge
method: derived
generated: '2026-10-09'
generator: derive-coverage.py (pre-flight evidence)
detail: the company's own front door answers a browser with an anti-bot challenge, so nothing behind it is reachable by
any reader
evidence:
- url: https://equityzen.com/company/carbonbiosciences
status: 403
x-enrichment:
date: '2026-10-09'
status: enriched
artifacts_added: 3
pass: modular-v1
engine: identity=local,contract=local,surfaces=local,docs=local,regulatory=local
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →